NewsEvents

Your Yourlocation: Home > Effect of tiotropium bromide(136310-93-5) on patients with moderate to severe chronic obstructive pulmonary disease

To evaluate the efficacy of tiotropium bromide(136310-93-5) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The use of tiotropium can significantly reduce the clinical symptoms of patients with stable COPD, improve lung function and improve the quality of life of patients. The article published in the 19th issue of 2015 "Chinese community physicians".

Sixty patients with stable COPD were randomly divided into experimental group and control group. The treatment group was treated with tiotropium bromide(136310-93-5) on the basis of routine therapy. The control group was treated with conventional therapy only for 12 weeks. The COPD score (CAT) The adverse effects were recorded in the St. George Quality of Life Questionnaire (SGRQ), pulmonary function tests such as forced expiratory volume in one second (FEV1) and forced expiratory volume in one second (FEV1 / FVC).

After treatment with tiotropium bromide(136310-93-5), the CAT and SGRQ scores decreased (6.9 ± 0.5) and (12.6 ± 0.7), respectively, compared with the control group (P <0.05). After inhalation of tiotropium bromide, FEV1, FEV1%, FEV1 / FVC were significantly improved in the experimental group compared with the control group (P <0.05). The main adverse events associated with tiotropium were dry mouth and the incidence was 10%.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved